SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Akums Drugs & Pharmaceuticals Ltd

BSE: 544222 NSE: AKUMS ISIN: INE09XN01023
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Akums Drugs & Pharmaceuticals Ltd belong to?
Akums Drugs & Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Akums Drugs & Pharmaceuticals Ltd a good quality company?
Akums Drugs & Pharmaceuticals Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Akums Drugs & Pharmaceuticals Ltd undervalued or overvalued?
Akums Drugs & Pharmaceuticals Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Akums Drugs & Pharmaceuticals Ltd a good buy now?
Akums Drugs & Pharmaceuticals Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd revenue growth is -9.2% for FY-2025 , which is below its 5 year CAGR of 12.2% , indicating slower growth.
Q.2 Gross Profit margin of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 18.9% for FY-2025 , which is above its 5 year median of 9.6% , indicating increasing margins.
Q.3 Operating Profit Margin of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 10.29% for FY-2025 , which is below its 5 year median of 11.37% indicating decreasing margins.
Q.4 Net Profit Margin of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd Net Profit Margin is 12.27% for FY-2025 , is above with its 5 year median of -11.46%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 18.9 9.6
Operating Profit Margin 10.29 11.37
Net Profit Margin 12.27 -11.46
Q.5 Return on Asset of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd Return on Asset is 6.74%, which is above its 5 year historical median of -8.3%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd Return on equity is 13.15% for FY-2025 , which is above its historical median of -22.73%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd Return on capital employed is 16.66% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd Cash conversion cycle is 52 days, below its historical median of 60 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.55 0.69
ROE 13.15 -22.73
ROCE 16.66 -20.46
Cash Conversion Cycle 52 days 60 days
Q.9 Debt to Equity ratio of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd Debt to cash flow from operations is 0.04 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Akums Drugs & Pharmaceuticals Ltd?
Promoters hold 75.26% of the Akums Drugs & Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Akums Drugs & Pharmaceuticals Ltd vs industry peers?
Akums Drugs & Pharmaceuticals Ltd revenue CAGR is 12.22% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 1,311.8 137.1
Gross Profit 248 15.1
Operating Profit 135 16
Net Profit 161 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.55 0.8
ROE 13.15 8.91
ROCE 16.66 11.59
Cash Conversion Cycle (days) 52.49 76

Valuation & price assessment

Q.1 Stock return of Akums Drugs & Pharmaceuticals Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of 12.27% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - 12.3%
Q.3 Valuation ratios of Akums Drugs & Pharmaceuticals Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 69.84 77.16 40.28
Price to Book 3.61 0.00 2.77
Price to Sales 6.47 7.52 2.65
EV to EBITDA 35.37 27.33 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×